Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
about
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigenDeletion of antigens of the Lewis a/b blood group family in human prostatic carcinomaTargeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24.Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.Human IgM antibody therapy for HIV-1 infection.Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1AMouse/human chimeric monoclonal antibody in man: kinetics and immune response.Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells.Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma CellsAndrogen-regulated transcriptional control of sialyltransferases in prostate cancer cellsMonoclonal antibodies--therapeutic and diagnostic uses in malignancy.Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers.Cell-surface antigens of melanoma recognized by human monoclonal antibodiesChimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients.Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems.Persistent complement activation on tumor cells in breast cancer.Immune recognition of self in immunity against cancer.Human anti-immunoglobulin antibodies interfering in immunometric assays.Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cellsCytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrinsO-acetylation of GD3: an enigmatic modification regulating apoptosis?Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.Role of gangliosides in active immunotherapy with melanoma vaccine.Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource DatabaseMelanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation.Tumorigenic human squamous lung cancer cells have defined cell surface carbohydrates that are absent from nontumorigenic cells.Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysisDisialyl gangliosides enhance tumor phenotypes with differential modalities.
P2860
Q24628627-E7259CF9-5FE4-4EC5-9168-D16B13959A35Q30444972-C65FBC29-3C59-4100-A00D-33FBE9598DDBQ30497901-1F390A55-BDA4-4642-8FD3-C4E279E84BF3Q30941602-5945824F-7382-4B70-A427-A3B1DF003EEBQ33557110-4C827F07-B381-40CC-A353-D1E833F5589CQ33753260-1517A844-9B24-4F56-9CBB-BD60E552277BQ33858524-1EA3332C-6628-4E42-8A02-BB6DA16675BCQ33867651-11D1B3C6-1DD4-481F-91C4-823980E4ED6EQ33904439-DCB00167-99F2-4D62-AED5-573D3BEDECA4Q34041344-89863520-286E-470E-9048-D59B062013B5Q34162748-CD35EFA6-8409-4EEF-A540-5DCD2F8C5B44Q34193200-FE06409E-7802-4C33-AAE9-FDA2963BB96FQ34478304-0485445D-454A-4AE3-BAED-8DF194B2F58BQ34504625-8863CDFB-36EB-4DCE-B894-C57EB00E5553Q34550428-AE72DC96-D142-49C7-86B5-BB7677AE64E3Q34614430-0987FB7D-B149-4678-B488-6A974066BE24Q34625006-C752D7B9-0ACC-4483-AA23-56412766B566Q34770185-B88A6431-B88B-4516-851C-2A9B3C123A37Q35146595-78C2F59D-1BDB-4E85-96E8-730F880BE28FQ35304730-AF573D69-F170-4BA2-81A2-76CB84FBB321Q35600422-9DF12173-FA84-4A7B-A20E-66B90330D533Q35799094-252BE82C-3549-4BB9-9FFF-8103A4A758ABQ35811297-8A78A98D-5BF8-40B6-844C-6E8945D8A63DQ35816141-7B7CE317-228E-4864-90FC-6966738F6826Q35831680-BD997F36-288C-47DA-B7E8-C30B317AFE4EQ35864865-9F81734E-9E77-4FD0-B53A-A49249943661Q36218992-0FA9BB1F-5C45-403C-ADFA-74D316B37CCBQ36219616-C97B9405-DCC7-4B71-AFBE-AE021E8C57ADQ36221549-6EA3230F-6230-439B-B791-9BB568912B68Q36376625-E24B1B68-1232-4747-885B-0AE62F4FEEABQ36431698-B1D94C2E-038D-434A-A3B9-F2C02D13BDFDQ36930077-5D1476BC-7A34-47AC-A6A3-277F0EFBC8C2Q37105366-D03E18CC-E2FD-40B9-AE78-FEE8E58FF44BQ37372067-1106FF06-2DC8-43B2-A187-CE99B3837C2EQ37400018-BD9B0394-50C6-4FD7-9518-4EEB9B432C54Q37403988-74AAD440-6D4F-4729-B75E-DAA6C9494D92Q37409943-1125A6DD-58F3-44F3-B9C7-284FA3533913Q37485741-D6A30861-AC49-408A-A9A5-95ECD73036D2Q37526231-5BC8862E-FF1D-43E0-A49F-00AD6E4E4B39Q38024047-6DFBD433-E08E-42CB-98BD-51357BFE7258
P2860
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1985
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@en
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@nl
type
label
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@en
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@nl
prefLabel
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@en
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@nl
P2093
P2860
P921
P356
P1476
Mouse monoclonal IgG3 antibody ...... ients with malignant melanoma.
@en
P2093
A N Houghton
C Cordon-Cardo
E Carswell
H F Oettgen
M R Melamed
P2860
P304
P356
10.1073/PNAS.82.4.1242
P407
P577
1985-02-01T00:00:00Z